<VariationArchive RecordType="classified" VariationID="30307" VariationName="NM_005902.4(SMAD3):c.741_742del (p.Phe248fs)" VariationType="Deletion" Accession="VCV000030307" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-11-05" DateCreated="2014-11-17" MostRecentSubmission="2014-11-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="39263" VariationID="30307">
      <GeneList>
        <Gene Symbol="SMAD3" FullName="SMAD family member 3" GeneID="4088" HGNC_ID="HGNC:6769" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>15q22.33</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="67065602" stop="67195169" display_start="67065602" display_stop="67195169" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="67358194" stop="67487532" display_start="67358194" display_stop="67487532" Strand="+" />
          </Location>
          <OMIM>603109</OMIM>
          <Haploinsufficiency last_evaluated="2020-04-22" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SMAD3">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-04-22" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SMAD3">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_005902.4(SMAD3):c.741_742del (p.Phe248fs)</Name>
      <CanonicalSPDI>NC_000015.10:67181322:AT:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>15q22.33</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="67181323" stop="67181324" display_start="67181323" display_stop="67181324" variantLength="2" positionVCF="67181322" referenceAlleleVCF="CAT" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="67473661" stop="67473662" display_start="67473661" display_stop="67473662" variantLength="2" positionVCF="67473660" referenceAlleleVCF="CAT" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>F204fs</ProteinChange>
      <ProteinChange>F143fs</ProteinChange>
      <ProteinChange>F248fs</ProteinChange>
      <ProteinChange>F53fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.10" sequenceAccession="NC_000015" sequenceVersion="10" change="g.67181323_67181324del" Assembly="GRCh38">
            <Expression>NC_000015.10:g.67181323_67181324del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.9" sequenceAccession="NC_000015" sequenceVersion="9" change="g.67473661_67473662del" Assembly="GRCh37">
            <Expression>NC_000015.9:g.67473661_67473662del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011990.1" sequenceAccession="NG_011990" sequenceVersion="1" change="g.120467_120468del">
            <Expression>NG_011990.1:g.120467_120468del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001145102.2" sequenceAccession="NM_001145102" sequenceVersion="2" change="c.426_427del">
            <Expression>NM_001145102.2:c.426_427del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001138574.1" sequenceAccession="NP_001138574" sequenceVersion="1" change="p.Phe143fs">
            <Expression>NP_001138574.1:p.Phe143fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001145103.2" sequenceAccession="NM_001145103" sequenceVersion="2" change="c.609_610del">
            <Expression>NM_001145103.2:c.609_610del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001138575.1" sequenceAccession="NP_001138575" sequenceVersion="1" change="p.Phe204fs">
            <Expression>NP_001138575.1:p.Phe204fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001145104.2" sequenceAccession="NM_001145104" sequenceVersion="2" change="c.156_157del">
            <Expression>NM_001145104.2:c.156_157del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001138576.1" sequenceAccession="NP_001138576" sequenceVersion="1" change="p.Phe53fs">
            <Expression>NP_001138576.1:p.Phe53fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_005902.4" sequenceAccession="NM_005902" sequenceVersion="4" change="c.741_742del" MANESelect="true">
            <Expression>NM_005902.4:c.741_742del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_005893.1" sequenceAccession="NP_005893" sequenceVersion="1" change="p.Phe248fs">
            <Expression>NP_005893.1:p.Phe248fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA020105" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="603109.0002" DB="OMIM" />
        <XRef Type="rs" ID="587776880" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_005902.4(SMAD3):c.741_742del (p.Phe248fs) AND Aneurysm-osteoarthritis syndrome" Accession="RCV000023242" Version="4">
        <ClassifiedConditionList TraitSetID="7467">
          <ClassifiedCondition DB="MedGen" ID="C3151087">Aneurysm-osteoarthritis syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2011-02-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2011-02-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2014-11-17" MostRecentSubmission="2014-11-17">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">21217753</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="7467" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="16102" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">ANEURYSMS-OSTEOARTHRITIS SYNDROME</ElementValue>
                <XRef Type="MIM" ID="613795" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">LOEYS-DIETZ SYNDROME WITH OSTEOARTHRITIS</ElementValue>
                <XRef Type="MIM" ID="613795" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Loeys-Dietz syndrome 3</ElementValue>
                <XRef ID="Loeys-Dietz+syndrome%2C+type+1C/8764" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Loeys-Dietz syndrome, type 1C</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Aneurysm-osteoarthritis syndrome</ElementValue>
                <XRef ID="MONDO:0013426" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">LDS1C</ElementValue>
                <XRef Type="MIM" ID="613795" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">LDS3</ElementValue>
                <XRef Type="MIM" ID="613795" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">SMAD3</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Loeys-Dietz syndrome (LDS) is characterized by vascular findings (cerebral, thoracic, and abdominal arterial aneurysms and/or dissections), skeletal manifestations (pectus excavatum or pectus carinatum, scoliosis, joint laxity, arachnodactyly, talipes equinovarus, cervical spine malformation and/or instability), craniofacial features (widely spaced eyes, strabismus, bifid uvula / cleft palate, and craniosynostosis that can involve any sutures), and cutaneous findings (velvety and translucent skin, easy bruising, and dystrophic scars). Individuals with LDS are predisposed to widespread and aggressive arterial aneurysms and pregnancy-related complications including uterine rupture and death. Individuals with LDS can show a strong predisposition for allergic/inflammatory disease including asthma, eczema, and reactions to food or environmental allergens. There is also an increased incidence of gastrointestinal inflammation including eosinophilic esophagitis and gastritis or inflammatory bowel disease. Wide variation in the distribution and severity of clinical features can be seen in individuals with LDS, even among affected individuals within a family who have the same pathogenic variant.</Attribute>
                <XRef ID="NBK1133" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10997" />
                <XRef ID="10997" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301312</ID>
                <ID Source="BookShelf">NBK1133</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ESC, 2014">
                <ID Source="PubMed">25173340</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <XRef ID="284984" DB="Orphanet" />
              <XRef ID="C3151087" DB="MedGen" />
              <XRef ID="MONDO:0013426" DB="MONDO" />
              <XRef Type="MIM" ID="613795" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="49789" SubmissionDate="2014-11-14" DateLastUpdated="2014-11-17" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="603109.0002_LOEYS-DIETZ SYNDROME 3" title="SMAD3, 2-BP DEL, 741AT_LOEYS-DIETZ SYNDROME 3" />
        <ClinVarAccession Accession="SCV000044533" DateUpdated="2014-11-17" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2011-02-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In 3 Dutch sibs with arterial aneurysms and dissections and early-onset osteoarthritis (LDS3; 613795), van de Laar et al. (2011) identified heterozygosity for a 2-bp deletion (741delAT) in exon 6 of the SMAD3 gene, resulting in a frameshift and a premature termination sequence at codon 309 in exon 7 that removes nearly the complete MH2 domain (Thr247ProfsTer61). The deletion, which was presumably present in their affected deceased father, was not found in their unaffected mother or in 544 Dutch control chromosomes. Analysis of patient cDNA showed very weak mutant signal compared to wildtype, and treatment of patient fibroblast cultures with cycloheximide markedly increased the mutant signal, indicating that most of the abnormal RNA was subjected to nonsense messenger RNA decay and that a truncated SMAD3 protein was barely formed.</Attribute>
              <Citation>
                <ID Source="PubMed">21217753</ID>
              </Citation>
              <XRef DB="OMIM" ID="613795" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SMAD3" />
          </GeneList>
          <Name>SMAD3, 2-BP DEL, 741AT</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">2-BP DEL, 741AT</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="603109.0002" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">LOEYS-DIETZ SYNDROME 3</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="49789" TraitType="Disease" MappingType="Name" MappingValue="LOEYS-DIETZ SYNDROME 3" MappingRef="Preferred">
        <MedGen CUI="C3151087" Name="Aneurysm-osteoarthritis syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

